<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - EXENATIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>EXENATIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, or both, or with pioglitazone, or with both metformin and pioglitazone, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 micrograms twice daily for at least 1 month, then increased if necessary up to 10 micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart).</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                2 mg once weekly.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Type 2 diabetes mellitus in combination with basal insulin alone or with metformin or pioglitazone (or both)</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 micrograms twice daily for at least 1 month, then increased if necessary up to 10 micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart).</li>
            </ul>
          </section>
        </section>
        
            <section class="doseAdjustments">
                <h3>Dose adjustments due to interactions</h3>
              <p>Dose of concomitant sulfonylurea may need to be reduced.</p>
            </section>
        
        
        
            <section class="pharmacokinetics">
              <h3>Pharmacokinetics</h3>
              <p>Effect of <i>modified-release</i> exenatide injection (<i>Bydureon</i>
        <tm tmtype="reg"/>) may persist for 10&#8239;weeks after discontinuation.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>For <i>standard-release</i> injection, use with caution if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>For <i>standard-release</i> injection, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>For <i>modified-release</i> injection, avoid if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Ketoacidosis</li>
            <li>severe gastro-intestinal disease</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain and distension, agitation, antibody formation, asthenia, decreased appetite, diarrhoea, dizziness, dyspepsia, gastro-intestinal disturbances, gastro-oesophageal reflux disease, headache, hypoglycaemia, increased sweating, injection-site reactions, nausea, vomiting, weight loss,
              </p>
              <p>
                <strong>uncommon:</strong> Pancreatitis,
              </p>
              <p>
                <strong>rare:</strong> Alopecia,
              </p>
              <p>
                <strong>veryRare:</strong> Anaphylactic reactions,
              </p>
              <p>
                <strong>notKnown:</strong> Angioedema, constipation, dehydration, drowsiness, eructation, flatulence, pruritus, rash, renal impairment, taste disturbance, urticaria,
              </p>
        
        
            <section class="advice">
                <h3>Pancreatitis</h3>
              <p>Severe pancreatitis (sometimes fatal), including haemorrhagic or necrotising pancreatitis, has been reported rarely; discontinue permanently if pancreatitis is diagnosed.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
              <p>If a dose of the immediate-release medicine is missed, continue with the next scheduled dose&#8212;do not administer <b>after</b> a meal. </p>
            </section>
            <section class="generalPatientAdvice">
              <p>Patients changing from standard-release to modified-release exenatide formulation may experience initial transient increase in blood glucose.</p><p>Some oral medications should be taken at least 1 hour before or 4 hours after exenatide injection&#8212;consult product literature for details.</p><p>Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek prompt medical attention if symptoms such as abdominal pain, nausea, and vomiting develop.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA248</h3>
              <p outputclass="title">Exenatide modified-release for the treatment of type 2 diabetes mellitis (February 2012)</p> <p>Modified-release exenatide in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended for the treatment of type 2 diabetes, only when glycaemic control is inadequate and the patient has:</p> <ul> <li>a body mass index (BMI) &#8805;35&#8239;kg/m<sup>2</sup> (in those of European descent, with appropriate adjustment for other ethnic groups) and weight-related psychological or medical problems, <i>or</i> </li> <li>a BMI &lt; 35&#8239;kg/m<sup>2</sup>, and insulin would be unacceptable for occupational reasons, or weight loss would benefit other significant obesity-related comorbidities.</li> </ul> <p>Treatment with modified-release exenatide in a triple therapy regimen should be continued only if HbA<sub>1c</sub> concentration is reduced by at least 1 percentage point and a weight loss of at least 3% is achieved within 6 months of starting treatment.</p> <p>Modified-release exenatide in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended only if:</p> <ul> <li>treatment with metformin or a sulphonylurea is contra- indicated or not tolerated, <i>and</i> </li> <li>treatment with thiazolidinediones and dipeptidylpeptidase-4 inhibitors is contra-indicated or not tolerated.</li> </ul> <p>Modified-release exenatide in a dual therapy regimen should be continued only if HbA<sub>1c</sub> concentration is reduced by at least 1 percentage point within 6 months of starting treatment.</p><xref format="html" href="http://www.nice.org.uk/TA248">www.nice.org.uk/TA248</xref>
                <a href="http://www.nice.org.uk/TA248" target="_blank">www.nice.org.uk/TA248</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Elderly
          </li>
          <li>
            may cause weight loss greater than 1.5&#8239;kg weekly
          </li>
          <li>
            pancreatitis
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Women of child-bearing age should use effective contraception during treatment with modified-release exenatide and for 12 weeks after discontinuation.</p>
            </section>
      </section>












      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of EXENATIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76090"><a href="../medicinalForm/PHP76090.html" data-target="#PHP76090" data-action="load">Solution for injection</a></div>
            <div id="PHP76100"><a href="../medicinalForm/PHP76100.html" data-target="#PHP76100" data-action="load">Powder and solvent for suspension for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
